The FDA approved Novartis's FLT3 inhibitor midostaurin for acute myeloid leukaemia (AML). The multikinase inhibitor is the first targeted treatment for AML, and the first new FDA approval for AML in decades.The FLT3 kinase is mutated in around one-third of AML patients, and

中文翻译：

---

FDA批准首个针对急性粒细胞性白血病的靶向药物

FDA批准了诺华的FLT3抑制剂Midostaurin用于急性髓细胞性白血病（AML）。多激酶抑制剂是AML的第一个靶向治疗药物，也是数十年来美国FDA首次批准AML.FLT3激酶在大约三分之一的AML患者中发生了突变，并且